GSK2879552 2HCl is primarily investigated for its potential therapeutic applications in oncology. It functions as a lysine-specific demethylase 1 (LSD1) inhibitor, which plays a critical role in regulating gene expression and cell differentiation. By inhibiting LSD1, this compound is being explored for its ability to reactivate silenced tumor suppressor genes, thereby potentially halting the growth of cancer cells. It has shown promise in preclinical studies for treating certain types of cancers, particularly small cell lung cancer (SCLC) and acute myeloid leukemia (AML). Additionally, its mechanism of action is being studied for its potential to enhance the efficacy of other cancer therapies, such as immunotherapy, by modulating the tumor microenvironment. Research is ongoing to determine its safety, efficacy, and optimal dosing in clinical trials.